This is the authors' abstract. We don't add key points for this paper.
The estimated percentages of patients who are eligible for and who respond to checkpoint inhibitor drugs are higher than reported estimates for drugs approved for genome-driven oncology but remain modest. Future research should explore biomarkers to maximize the benefit of immunotherapy among patients receiving it.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Haslam et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: